Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress?
Management approaches for accelerated and blast phase myeloproliferative neoplasms remain challenging for clinicians and patients alike. Despite many therapeutic advances, outcomes for those patients who are not allogeneic haematopoietic cell transplant eligible remain, in general, very poor. Estima...
Saved in:
| Published in | British journal of haematology Vol. 203; no. 2; pp. 169 - 181 |
|---|---|
| Main Authors | , , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
Blackwell Publishing Ltd
01.10.2023
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Management approaches for accelerated and blast phase myeloproliferative neoplasms remain challenging for clinicians and patients alike. Despite many therapeutic advances, outcomes for those patients who are not allogeneic haematopoietic cell transplant eligible remain, in general, very poor. Estimated survival rates for such blast phase patients is frequently reported as less than 6 months. No specific immunological, genomic or clinicopathological signature currently exists that accurately predicts the risk and timing of transformation, which frequently induces a high degree of anxiety among patients and clinicians alike. Within this review article, we provide an up-to-date summary of current understanding of the underlying pathogenesis of accelerated and blast phase disease and discuss current therapeutic approaches and realistic outcomes. Finally, we discuss how the horizon may look with the introduction of more novel agents into the clinical arena. |
|---|---|
| AbstractList | Summary
Management approaches for accelerated and blast phase myeloproliferative neoplasms remain challenging for clinicians and patients alike. Despite many therapeutic advances, outcomes for those patients who are not allogeneic haematopoietic cell transplant eligible remain, in general, very poor. Estimated survival rates for such blast phase patients is frequently reported as less than 6 months. No specific immunological, genomic or clinicopathological signature currently exists that accurately predicts the risk and timing of transformation, which frequently induces a high degree of anxiety among patients and clinicians alike. Within this review article, we provide an up‐to‐date summary of current understanding of the underlying pathogenesis of accelerated and blast phase disease and discuss current therapeutic approaches and realistic outcomes. Finally, we discuss how the horizon may look with the introduction of more novel agents into the clinical arena. Management approaches for accelerated and blast phase myeloproliferative neoplasms remain challenging for clinicians and patients alike. Despite many therapeutic advances, outcomes for those patients who are not allogeneic haematopoietic cell transplant eligible remain, in general, very poor. Estimated survival rates for such blast phase patients is frequently reported as less than 6 months. No specific immunological, genomic or clinicopathological signature currently exists that accurately predicts the risk and timing of transformation, which frequently induces a high degree of anxiety among patients and clinicians alike. Within this review article, we provide an up‐to‐date summary of current understanding of the underlying pathogenesis of accelerated and blast phase disease and discuss current therapeutic approaches and realistic outcomes. Finally, we discuss how the horizon may look with the introduction of more novel agents into the clinical arena. |
| Author | Spiers, Jessica McLornan, Donal P Mahdi, Dina Polverelli, Nicola Rampotas, Alexandros |
| Author_xml | – sequence: 1 givenname: Dina surname: Mahdi fullname: Mahdi, Dina organization: Department of Haematology, University College Hospital, London, UK – sequence: 2 givenname: Jessica surname: Spiers fullname: Spiers, Jessica organization: Department of Haematology, University College Hospital, London, UK – sequence: 3 givenname: Alexandros surname: Rampotas fullname: Rampotas, Alexandros organization: Department of Haematology, University College Hospital, London, UK – sequence: 4 givenname: Nicola orcidid: 0000-0001-6297-9697 surname: Polverelli fullname: Polverelli, Nicola organization: Unit of Blood Diseases and Stem Cell Transplantation, University of Brescia, Brescia, Italy – sequence: 5 givenname: Donal P orcidid: 0000-0003-1224-091X surname: McLornan fullname: McLornan, Donal P organization: Department of Haematology, University College Hospital, London, UK |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/37527977$$D View this record in MEDLINE/PubMed |
| BookMark | eNpd0ElLAzEUB_AgFbvowS8gAS96mJqXTGbxIqW4QcGLvQlDJvOmnTqbyYzSb29qqwdzeQR-vOU_JoO6qZGQc2BTcO8m3aynEDNgR2QEIpAeBx8GZMQYCz1gfjQkY2s3jIFgEk7IUISSh3EYjsjbss1Uh5Y2NVVaY4nGfTOq6oympbIdbdfKIq22WDatacoi34niE2mNTetEZW_pzCD9cki9F_WKOrYyaO3dKTnOVWnx7FAnZPlw_zp_8hYvj8_z2cLTPBSdlzEBkIkoBoiQa8lV7CsW8DyXuR_EgdZpiugDxBDKXIhMqlQHOU-ljgIuMjEhV_u-bvJHj7ZLqsK6W0rlduxtwiNfAhPMl45e_qObpje1286pkEMkWMSdut4rbRprDeZJa4pKmW0CLNlFnrjIk5_Inb04dOzTCrM_-Zux-AaLv31V |
| Cites_doi | 10.1002/cncr.33689 10.1046/j.0007-1048.2001.03319.x 10.1016/j.jtct.2021.11.006 10.1182/blood-2022-169050 10.1182/blood-2011-01-331678 10.3389/fimmu.2021.683401 10.1182/blood-2008-02-138230 10.1111/bjh.17423 10.1056/NEJMoa1716614 10.1182/bloodadvances.2018015875 10.1002/ajh.26548 10.1097/01.HS9.0000845176.08161.c8 10.1182/blood-2009-09-245837 10.1182/blood-2009-08-236596 10.1182/bloodadvances.2021005491 10.1159/000512929 10.1016/j.bbmt.2009.12.004 10.1002/cncr.33094 10.1182/blood.V114.22.435.435 10.1158/1078-0432.CCR-08-2783 10.1126/scitranslmed.aba4380 10.1182/blood-2006-12-062125 10.1038/leu.2010.77 10.1038/leu.2011.320 10.1016/j.clml.2017.07.179 10.1016/j.bbmt.2016.09.017 10.1002/ajh.26833 10.1038/s41409-020-0934-1 10.1046/j.1365-2141.2000.01826.x 10.1111/j.1365-2141.2005.05674.x 10.1200/JCO.2017.76.4886 10.1182/bloodadvances.2020002271 10.1200/JCO.2010.32.2446 10.2147/OTT.S100515 10.1182/blood.2021014465 10.1038/nature09504 10.1038/s41375-018-0107-z 10.1182/bloodadvances.2020002119 10.1182/blood-2014-05-579136 10.1182/blood-2022-159092 10.1038/bmt.2014.31 10.1200/JCO.22.01972 10.1111/bjh.16185 10.1038/s41375-018-0019-y 10.1200/JCO.2010.34.5298 10.1007/s00277-021-04683-w 10.3389/fonc.2021.637420 10.1016/j.mayocp.2017.05.010 10.1038/s41408-019-0175-y 10.3390/cells10123551 10.1016/j.leukres.2015.03.001 10.1111/bjh.13046 10.1200/JCO.2022.40.16_suppl.TPS7063 10.3390/ijms20081839 10.1182/blood-2013-11-537167 10.1182/blood-2012-10-464248 10.1038/s41375-022-01613-1 10.1016/j.leukres.2015.06.001 10.1182/blood-2010-03-274811 10.1111/bjh.16709 10.1182/blood-2021-153071 10.1038/leu.2016.260 10.1111/bjh.15819 10.1038/leu.2010.113 10.3324/haematol.2016.152363 10.1182/hematology.2021000257 10.1182/blood-2022-160222 10.1182/blood-2022-159435 10.3390/cancers14051241 10.1111/bjh.16380 10.1182/blood.2022016490 10.1073/pnas.1407792111 10.1200/JCO.2017.77.6112 10.1182/blood-2004-07-2864 10.1038/leu.2013.163 10.1182/blood-2020-140771 10.1038/s41375-020-0778-0 10.1182/bloodadvances.2020001528 10.1038/sj.leu.2404500 10.1101/2022.03.28.485984 10.1016/j.bbmt.2013.10.027 10.1155/2015/102476 10.1182/blood-2020-138437 10.1158/2159-8290.CD-20-1652 10.3389/fimmu.2023.1117466 10.1158/2159-8290.CD-20-1465 10.1200/JCO.2018.78.9867 10.1038/s41375-021-01294-2 10.1182/bloodadvances.2020002621 10.1080/07853890.2022.2164611 10.1182/hematology.2022000354 |
| ContentType | Journal Article |
| Copyright | 2023 British Society for Haematology and John Wiley & Sons Ltd. |
| Copyright_xml | – notice: 2023 British Society for Haematology and John Wiley & Sons Ltd. |
| DBID | NPM AAYXX CITATION 7T5 H94 7X8 |
| DOI | 10.1111/bjh.19010 |
| DatabaseName | PubMed CrossRef Immunology Abstracts AIDS and Cancer Research Abstracts MEDLINE - Academic |
| DatabaseTitle | PubMed CrossRef AIDS and Cancer Research Abstracts Immunology Abstracts MEDLINE - Academic |
| DatabaseTitleList | CrossRef AIDS and Cancer Research Abstracts PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1365-2141 |
| EndPage | 181 |
| ExternalDocumentID | 10_1111_bjh_19010 37527977 |
| Genre | Journal Article Review |
| GroupedDBID | --- .3N .GA 05W 0R~ 10A 1OB 1OC 23N 24P 33P 36B 3SF 4.4 50Y 50Z 51W 51X 52M 52N 52O 52P 52R 52S 52T 52U 52V 52W 52X 53G 5GY 5HH 5LA 5RE 5VS 66C 6J9 6P2 702 7PT 8-0 8-1 8-3 8-4 8-5 8UM 930 A01 A03 AAESR AAEVG AAHHS AANLZ AAONW AAXRX AAYEP AAZKR ABCQN ABCUV ABEML ABJNI ABLJU ABOCM ABPVW ABQWH ABXGK ACAHQ ACCFJ ACCZN ACFBH ACGFO ACGFS ACGOF ACMXC ACPOU ACPRK ACSCC ACXBN ACXQS ADBBV ADBTR ADEOM ADIZJ ADKYN ADMGS ADOZA ADXAS ADZMN ADZOD AEEZP AEGXH AEIGN AEIMD AENEX AEQDE AEUQT AEUYR AFBPY AFEBI AFFPM AFGKR AFPWT AFRAH AFZJQ AHBTC AIACR AIAGR AITYG AIURR AIWBW AJBDE ALAGY ALMA_UNASSIGNED_HOLDINGS ALUQN AMBMR AMYDB ATUGU AZBYB AZVAB BAFTC BDRZF BFHJK BHBCM BMXJE BROTX BRXPI BY8 C45 CS3 D-6 D-7 D-E D-F DCZOG DPXWK DR2 DRFUL DRMAN DRSTM DU5 EBS EMOBN ESX EX3 F00 F01 F04 F5P FUBAC G-S G.N GODZA H.X HGLYW HZI HZ~ IH2 IHE IX1 J0M J5H K48 KBYEO L7B LATKE LC2 LC3 LEEKS LH4 LITHE LOXES LP6 LP7 LUTES LYRES MEWTI MK4 MRFUL MRMAN MRSTM MSFUL MSMAN MSSTM MXFUL MXMAN MXSTM N04 N05 N9A NF~ NPM O66 O9- OIG OK1 OVD P2P P2W P2X P2Z P4B P4D Q.N Q11 QB0 R.K ROL RX1 SUPJJ TEORI UB1 V8K V9Y W8V W99 WBKPD WHWMO WIH WIJ WIK WIN WOHZO WOW WQJ WRC WUP WVDHM WXI WXSBR XG1 YFH YOC YUY ZZTAW ~IA ~WT .55 .GJ .Y3 1KJ 31~ 3O- 8F7 AAKAS AASGY AAYXX ACBWZ ADZCM AFFNX AHEFC AI. ASPBG AVWKF AZFZN CAG CITATION COF EGARE EJD FEDTE FZ0 HF~ HVGLF LW6 N4W PALCI RIWAO RJQFR SAMSI VH1 X7M ZGI ZXP 7T5 H94 7X8 |
| ID | FETCH-LOGICAL-c273t-d0311d389118e2c52a94a062ff5f4696ccbbee4119175f33d5abc6f2b5c8623d3 |
| ISSN | 0007-1048 |
| IngestDate | Fri Oct 25 03:01:45 EDT 2024 Thu Oct 10 19:10:40 EDT 2024 Fri Aug 23 03:48:52 EDT 2024 Sat Sep 28 08:14:25 EDT 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | AML accelerated phase blast phase polycythaemia vera MPN JAK2 essential thrombocythaemia |
| Language | English |
| License | 2023 British Society for Haematology and John Wiley & Sons Ltd. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c273t-d0311d389118e2c52a94a062ff5f4696ccbbee4119175f33d5abc6f2b5c8623d3 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-3 content type line 23 ObjectType-Review-1 |
| ORCID | 0000-0003-1224-091X 0000-0001-6297-9697 |
| PMID | 37527977 |
| PQID | 2872183082 |
| PQPubID | 36395 |
| PageCount | 13 |
| ParticipantIDs | proquest_miscellaneous_2845103045 proquest_journals_2872183082 crossref_primary_10_1111_bjh_19010 pubmed_primary_37527977 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-10-01 |
| PublicationDateYYYYMMDD | 2023-10-01 |
| PublicationDate_xml | – month: 10 year: 2023 text: 2023-10-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: Oxford |
| PublicationTitle | British journal of haematology |
| PublicationTitleAlternate | Br J Haematol |
| PublicationYear | 2023 |
| Publisher | Blackwell Publishing Ltd |
| Publisher_xml | – name: Blackwell Publishing Ltd |
| References | e_1_2_13_24_1 e_1_2_13_49_1 e_1_2_13_26_1 e_1_2_13_47_1 e_1_2_13_68_1 e_1_2_13_20_1 e_1_2_13_45_1 e_1_2_13_66_1 e_1_2_13_87_1 e_1_2_13_22_1 e_1_2_13_43_1 e_1_2_13_64_1 e_1_2_13_85_1 e_1_2_13_8_1 e_1_2_13_41_1 e_1_2_13_62_1 e_1_2_13_60_1 e_1_2_13_83_1 e_1_2_13_6_1 e_1_2_13_81_1 e_1_2_13_90_1 e_1_2_13_92_1 e_1_2_13_17_1 e_1_2_13_19_1 e_1_2_13_13_1 e_1_2_13_36_1 e_1_2_13_59_1 e_1_2_13_15_1 e_1_2_13_38_1 e_1_2_13_57_1 e_1_2_13_32_1 e_1_2_13_55_1 e_1_2_13_78_1 e_1_2_13_11_1 e_1_2_13_34_1 e_1_2_13_53_1 e_1_2_13_76_1 e_1_2_13_51_1 e_1_2_13_74_1 e_1_2_13_30_1 e_1_2_13_72_1 e_1_2_13_70_1 e_1_2_13_4_1 e_1_2_13_2_1 e_1_2_13_88_1 e_1_2_13_29_1 e_1_2_13_25_1 e_1_2_13_48_1 e_1_2_13_27_1 e_1_2_13_46_1 e_1_2_13_69_1 e_1_2_13_21_1 e_1_2_13_44_1 e_1_2_13_67_1 e_1_2_13_23_1 e_1_2_13_42_1 e_1_2_13_65_1 e_1_2_13_86_1 e_1_2_13_9_1 e_1_2_13_40_1 e_1_2_13_63_1 e_1_2_13_84_1 e_1_2_13_7_1 e_1_2_13_61_1 e_1_2_13_82_1 e_1_2_13_80_1 e_1_2_13_91_1 e_1_2_13_18_1 e_1_2_13_39_1 e_1_2_13_14_1 e_1_2_13_35_1 e_1_2_13_16_1 e_1_2_13_37_1 e_1_2_13_58_1 e_1_2_13_79_1 e_1_2_13_10_1 e_1_2_13_31_1 e_1_2_13_56_1 e_1_2_13_77_1 e_1_2_13_12_1 e_1_2_13_33_1 e_1_2_13_54_1 e_1_2_13_75_1 e_1_2_13_52_1 e_1_2_13_73_1 e_1_2_13_50_1 e_1_2_13_71_1 e_1_2_13_5_1 e_1_2_13_3_1 e_1_2_13_89_1 e_1_2_13_28_1 |
| References_xml | – ident: e_1_2_13_64_1 doi: 10.1002/cncr.33689 – ident: e_1_2_13_47_1 doi: 10.1046/j.0007-1048.2001.03319.x – ident: e_1_2_13_43_1 doi: 10.1016/j.jtct.2021.11.006 – ident: e_1_2_13_74_1 doi: 10.1182/blood-2022-169050 – ident: e_1_2_13_28_1 doi: 10.1182/blood-2011-01-331678 – ident: e_1_2_13_38_1 doi: 10.3389/fimmu.2021.683401 – ident: e_1_2_13_58_1 doi: 10.1182/blood-2008-02-138230 – ident: e_1_2_13_88_1 doi: 10.1111/bjh.17423 – ident: e_1_2_13_18_1 doi: 10.1056/NEJMoa1716614 – ident: e_1_2_13_26_1 doi: 10.1182/bloodadvances.2018015875 – ident: e_1_2_13_21_1 doi: 10.1002/ajh.26548 – ident: e_1_2_13_65_1 doi: 10.1097/01.HS9.0000845176.08161.c8 – ident: e_1_2_13_19_1 doi: 10.1182/blood-2009-09-245837 – ident: e_1_2_13_31_1 doi: 10.1182/blood-2009-08-236596 – ident: e_1_2_13_84_1 doi: 10.1182/bloodadvances.2021005491 – ident: e_1_2_13_6_1 doi: 10.1159/000512929 – ident: e_1_2_13_92_1 doi: 10.1016/j.bbmt.2009.12.004 – ident: e_1_2_13_4_1 doi: 10.1002/cncr.33094 – ident: e_1_2_13_24_1 doi: 10.1182/blood.V114.22.435.435 – ident: e_1_2_13_46_1 doi: 10.1158/1078-0432.CCR-08-2783 – ident: e_1_2_13_82_1 doi: 10.1126/scitranslmed.aba4380 – ident: e_1_2_13_32_1 doi: 10.1182/blood-2006-12-062125 – ident: e_1_2_13_23_1 doi: 10.1038/leu.2010.77 – ident: e_1_2_13_27_1 doi: 10.1038/leu.2011.320 – ident: e_1_2_13_5_1 doi: 10.1016/j.clml.2017.07.179 – ident: e_1_2_13_90_1 doi: 10.1016/j.bbmt.2016.09.017 – ident: e_1_2_13_42_1 doi: 10.1002/ajh.26833 – ident: e_1_2_13_45_1 doi: 10.1038/s41409-020-0934-1 – ident: e_1_2_13_60_1 doi: 10.1046/j.1365-2141.2000.01826.x – ident: e_1_2_13_39_1 doi: 10.1111/j.1365-2141.2005.05674.x – ident: e_1_2_13_16_1 doi: 10.1200/JCO.2017.76.4886 – ident: e_1_2_13_13_1 doi: 10.1182/bloodadvances.2020002271 – ident: e_1_2_13_20_1 doi: 10.1200/JCO.2010.32.2446 – ident: e_1_2_13_78_1 doi: 10.2147/OTT.S100515 – ident: e_1_2_13_34_1 doi: 10.1182/blood.2021014465 – ident: e_1_2_13_77_1 doi: 10.1038/nature09504 – ident: e_1_2_13_15_1 doi: 10.1038/s41375-018-0107-z – ident: e_1_2_13_53_1 doi: 10.1182/bloodadvances.2020002119 – ident: e_1_2_13_9_1 doi: 10.1182/blood-2014-05-579136 – ident: e_1_2_13_87_1 doi: 10.1182/blood-2022-159092 – ident: e_1_2_13_91_1 doi: 10.1038/bmt.2014.31 – ident: e_1_2_13_79_1 doi: 10.1200/JCO.22.01972 – ident: e_1_2_13_59_1 doi: 10.1111/bjh.16185 – ident: e_1_2_13_2_1 doi: 10.1038/s41375-018-0019-y – ident: e_1_2_13_7_1 doi: 10.1200/JCO.2010.34.5298 – ident: e_1_2_13_75_1 doi: 10.1007/s00277-021-04683-w – ident: e_1_2_13_81_1 doi: 10.3389/fonc.2021.637420 – ident: e_1_2_13_11_1 doi: 10.1016/j.mayocp.2017.05.010 – ident: e_1_2_13_22_1 doi: 10.1038/s41408-019-0175-y – ident: e_1_2_13_25_1 doi: 10.3390/cells10123551 – ident: e_1_2_13_50_1 doi: 10.1016/j.leukres.2015.03.001 – ident: e_1_2_13_52_1 doi: 10.1111/bjh.13046 – ident: e_1_2_13_73_1 doi: 10.1200/JCO.2022.40.16_suppl.TPS7063 – ident: e_1_2_13_10_1 doi: 10.3390/ijms20081839 – ident: e_1_2_13_33_1 doi: 10.1182/blood-2013-11-537167 – ident: e_1_2_13_56_1 doi: 10.1182/blood-2012-10-464248 – ident: e_1_2_13_3_1 doi: 10.1038/s41375-022-01613-1 – ident: e_1_2_13_49_1 doi: 10.1016/j.leukres.2015.06.001 – ident: e_1_2_13_48_1 doi: 10.1182/blood-2010-03-274811 – ident: e_1_2_13_71_1 doi: 10.1111/bjh.16709 – ident: e_1_2_13_72_1 doi: 10.1182/blood-2021-153071 – ident: e_1_2_13_80_1 doi: 10.1038/leu.2016.260 – ident: e_1_2_13_89_1 doi: 10.1111/bjh.15819 – ident: e_1_2_13_69_1 doi: 10.1038/leu.2010.113 – ident: e_1_2_13_30_1 doi: 10.3324/haematol.2016.152363 – ident: e_1_2_13_44_1 doi: 10.1182/hematology.2021000257 – ident: e_1_2_13_67_1 doi: 10.1182/blood-2022-160222 – ident: e_1_2_13_85_1 doi: 10.1182/blood-2022-159435 – ident: e_1_2_13_86_1 doi: 10.3390/cancers14051241 – ident: e_1_2_13_14_1 doi: 10.1111/bjh.16380 – ident: e_1_2_13_35_1 doi: 10.1182/blood.2022016490 – ident: e_1_2_13_29_1 doi: 10.1073/pnas.1407792111 – ident: e_1_2_13_68_1 doi: 10.1200/JCO.2017.77.6112 – ident: e_1_2_13_57_1 doi: 10.1182/blood-2004-07-2864 – ident: e_1_2_13_8_1 doi: 10.1038/leu.2013.163 – ident: e_1_2_13_76_1 doi: 10.1182/blood-2020-140771 – ident: e_1_2_13_54_1 doi: 10.1038/s41375-020-0778-0 – ident: e_1_2_13_70_1 doi: 10.1182/bloodadvances.2020001528 – ident: e_1_2_13_12_1 doi: 10.1038/sj.leu.2404500 – ident: e_1_2_13_36_1 doi: 10.1101/2022.03.28.485984 – ident: e_1_2_13_41_1 doi: 10.1016/j.bbmt.2013.10.027 – ident: e_1_2_13_40_1 doi: 10.1155/2015/102476 – ident: e_1_2_13_55_1 doi: 10.1182/blood-2020-138437 – ident: e_1_2_13_37_1 doi: 10.1158/2159-8290.CD-20-1652 – ident: e_1_2_13_83_1 doi: 10.3389/fimmu.2023.1117466 – ident: e_1_2_13_66_1 doi: 10.1158/2159-8290.CD-20-1465 – ident: e_1_2_13_17_1 doi: 10.1200/JCO.2018.78.9867 – ident: e_1_2_13_61_1 doi: 10.1038/s41375-021-01294-2 – ident: e_1_2_13_62_1 doi: 10.1182/bloodadvances.2020002621 – ident: e_1_2_13_51_1 doi: 10.1080/07853890.2022.2164611 – ident: e_1_2_13_63_1 doi: 10.1182/hematology.2022000354 |
| SSID | ssj0013051 |
| Score | 2.465388 |
| SecondaryResourceType | review_article |
| Snippet | Management approaches for accelerated and blast phase myeloproliferative neoplasms remain challenging for clinicians and patients alike. Despite many... Summary Management approaches for accelerated and blast phase myeloproliferative neoplasms remain challenging for clinicians and patients alike. Despite many... |
| SourceID | proquest crossref pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 169 |
| SubjectTerms | Allografts Hematology Hematopoietic stem cells |
| Title | Updates on accelerated and blast phase myeloproliferative neoplasms: Are we making progress? |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/37527977 https://www.proquest.com/docview/2872183082 https://search.proquest.com/docview/2845103045 |
| Volume | 203 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1ba9swFBZZB2MvY_dl64Y29hYcbNmy472UUlrKIHsoDfRhYCRZIqzEDolD2X7GfvHOkeRL2xW6vZjga-zzcS7Sdz4R8jkzWueZlEGsTRgAKFggSxUHMp2VADAjdIj9zvNv6eki-XrBL0aj3wPW0q6RU_Xrr30l_2NV2Ad2xS7Zf7Bsd1PYAb_BvrAFC8P2XjZerLFetwP-QikIIKj7YLVXJxKy4mayXkKQmqx-Ii8Il-cx2gt9V0gcF9uVJcQdbvTkComsl641vbY1-A3KX6t-NJCaWAoUfL02Lj8Xy9K1rvtluduZ-Y3vG9tuB-SgM7Fa141rKfOdNhC0O29dI2sbBUM7yIrhIAXr6W69481gnxPVnGrnay3BLnK6V60zZmE8QB0buNbILenio3TkFnq5IwDIH8spZjphH-Xamf0bwa-jJLbFEFxa2EsfkIcMnJed-j9j_cxUyP0qjO6FvFoVssO6p17Pce4oXGwCc_6UPPGVBz10MHpGRrp6Th7NPbfiBfnu0UTrig7QRMEo1KKJWjTR22iiHZq-wO01vYKTLJZoi6WDl2Rxcnx-dBr4tTcCBQltE5Tg7KMSJ7GjmWaKM5EnIkyZMdwkaZ4qJaXWCcoDZtzEccmFVKlhkiuokeMyfkX2qrrSbwidCYxkORzI8ySDjBcqWskhM5a5NJFOxuRT-7WKtZNYKW5ZY0z22-9YeKBvC6j2McOHLHZMPnaHwT_ipJeAd9_hOQmKRkLlMiav3ffvnhJnHEycZW_v8w_ekcc9svfJXrPZ6feQkDbyg0XIH5h0jkc |
| link.rule.ids | 315,783,787,27936,27937 |
| linkProvider | Wiley-Blackwell |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Updates+on+accelerated+and+blast+phase+myeloproliferative+neoplasms%3A+Are+we+making+progress%3F&rft.jtitle=British+journal+of+haematology&rft.au=Mahdi%2C+Dina&rft.au=Spiers%2C+Jessica&rft.au=Rampotas%2C+Alexandros&rft.au=Polverelli%2C+Nicola&rft.date=2023-10-01&rft.issn=0007-1048&rft.eissn=1365-2141&rft.volume=203&rft.issue=2&rft.spage=169&rft.epage=181&rft_id=info:doi/10.1111%2Fbjh.19010&rft.externalDBID=n%2Fa&rft.externalDocID=10_1111_bjh_19010 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0007-1048&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0007-1048&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0007-1048&client=summon |